<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Physiology of somatostatin and its analogues</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Physiology of somatostatin and its analogues</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Physiology of somatostatin and its analogues</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodger A Liddle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Somatostatin holds an interesting place in gastrointestinal endocrinology. Originally discovered as an inhibitor of growth hormone release [<a href="#rid1">1</a>], it is now known to inhibit a variety of gastrointestinal processes (<a class="graphic graphic_table graphicRef67174" href="/d/graphic/67174.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. Somatostatin is produced by paracrine cells that are scattered throughout the gastrointestinal tract and inhibits gastrointestinal endocrine secretion. Somatostatin is also found in various locations in the nervous system and exerts neural control over many physiological functions. Given this vast array of effects, it is not surprising that somatostatin has been the subject of intensive investigation. The development of synthetic analogues has led to treatment of clinical disorders such as acromegaly, hormone-secreting tumors of the gastrointestinal tract, and portal hypertensive bleeding.</p><p class="headingAnchor" id="H2"><span class="h1">MOLECULAR FORMS</span><span class="headingEndMark"> — </span>Biologically active somatostatin exists in two molecular forms: somatostatin-14 and somatostatin-28. Both are the products of post-translational processing of preprohormone [<a href="#rid3">3</a>] (see  <a class="medical medical_review" href="/d/html/2534.html" rel="external">"Overview of gastrointestinal peptides in health and disease"</a>). Somatostatin is a cyclic peptide (<a class="graphic graphic_figure graphicRef55724" href="/d/graphic/55724.html" rel="external">figure 1</a>) that is remarkably well conserved in evolution. A disulfide bond between cysteine residues maintains the cyclic structure. Somatostatin-14 is identical to the carboxyl terminal 14 amino acids of somatostatin-28. The biological activity of S-14 and S-28 resides in the cyclic region of the mature peptide. The F-W-K-T portion of the ring structure is required for receptor occupancy. This finding made it possible to produce synthetic bioactive peptides such as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> acetate (SMS-201-995, Sandostatin) (<a class="graphic graphic_figure graphicRef55724" href="/d/graphic/55724.html" rel="external">figure 1</a>).</p><p>Cortistatin is a neuropeptide that is structurally similar to somatostatin and binds to all somatostatin receptor subtypes. It can also bind the growth hormone secretagogue receptor (GHS-R, also known as the ghrelin receptor), but as yet its physiological function is unknown [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h1">TISSUE DISTRIBUTION</span><span class="headingEndMark"> — </span>Somatostatin is distributed throughout the entire body, although it is particularly abundant in nervous tissue of the cortex, hypothalamus, brainstem, and spinal cord. It has also been localized in nerves of the heart, thyroid, skin, eye, and thymus. Somatostatin is abundant in the gastrointestinal tract and pancreas where it is produced by paracrine and endocrine-like D cells and by enteric nerves. Both S-14 and S-28 are expressed throughout regions of the gastrointestinal tract.</p><p>Somatostatin cells are morphologically diverse. In the gut mucosa, D-cells are flask-shaped and contain long cytoplasmic extensions that end in nerve terminal-like processes poised to participate in endocrine regulation either via release into the systemic circulation or direct secretion onto a neighboring cell (see  <a class="medical medical_review" href="/d/html/2534.html" rel="external">"Overview of gastrointestinal peptides in health and disease"</a>). These cells appear uniquely suited to sample the luminal contents and influence local cell responses in a paracrine manner. In the central and peripheral nervous systems, nerves release somatostatin where it functions as a peptidergic neurotransmitter.</p><p class="headingAnchor" id="H4"><span class="h1">RECEPTORS</span><span class="headingEndMark"> — </span>The somatostatin receptor is a typical G protein-coupled receptor (see  <a class="medical medical_review" href="/d/html/3804.html" rel="external">"Peptide hormone signal transduction and regulation"</a>). At present there are five known subtypes of the somatostatin receptor (designated subtypes 1 to 5). These receptors do not differ appreciably in their binding of somatostatin 14 or 28; however, there is significant variation in binding of synthetic somatostatin peptides [<a href="#rid2">2,5</a>]. All somatostatin receptor subtypes have been found in the brain [<a href="#rid6">6</a>]. In contrast, peripheral tissues vary in the subtype expressed (<a class="graphic graphic_table graphicRef75201" href="/d/graphic/75201.html" rel="external">table 2</a>).</p><p>All subtypes of the somatostatin receptor are coupled to adenylate cyclase through an inhibitory G protein (see  <a class="medical medical_review" href="/d/html/3804.html" rel="external">"Peptide hormone signal transduction and regulation"</a>). Receptor activation results in a reduction of cAMP accumulation. In addition, agonist occupancy of some subtypes couples to activation of ion channels (eg, potassium channels) and mobilization of intracellular calcium [<a href="#rid3">3</a>].</p><p>Certain agonists exhibit functional selectivity at individual somatostatin receptors and activate only a portion of the receptor's potential effects. This property is known as selective agonism, and has been described with other G protein-coupled receptors [<a href="#rid7">7</a>]. This may make it possible to develop agonists with various somatostatin-like activities.</p><p>Interestingly, somatostatin receptors can interact with each other and form dimers [<a href="#rid8">8</a>]. Agonist-induced receptor dimerization changes ligand binding affinity and receptor internalization [<a href="#rid8">8</a>]. Different receptor types can interact with the somatostatin receptor (receptor heterodimerization), thus, providing a novel pathway for cellular communication. As an example, the dopamine receptor (type 2) and the somatostatin receptor (type 5) can physically associate to diversify receptor signaling [<a href="#rid9">9</a>]. Cross-talk between somatostatin receptors and growth factor receptors of the receptor tyrosine kinase (RTK) family may be important in cancer [<a href="#rid10">10</a>].</p><p>The effects of somatostatin on protein tyrosine phosphatases including the Src homology phosphatases, SHP-1 and SHP-2, appear to counteract growth factor stimulated tyrosine kinase activity and thereby inhibit mitogenic signaling pathways and contribute to the antiproliferative effects of somatostatin and analogues on tumor growth [<a href="#rid11">11</a>]. Somatostatin treatment causes desensitization and internalization of somatostatin receptors within minutes [<a href="#rid12">12</a>]. This process may contribute to refractoriness to chronic somatostatin administration.</p><p class="headingAnchor" id="H5"><span class="h1">SOMATOSTATIN RELEASE</span><span class="headingEndMark"> — </span>Somatostatin is a key regulatory peptide that functions primarily as a paracrine mediator (see  <a class="medical medical_review" href="/d/html/3804.html" rel="external">"Peptide hormone signal transduction and regulation"</a>). It is released from neural, endocrine, and enteroendocrine cells and has a short half-life in tissue and in blood. Its concentration in the blood is low, generally in sub-picomolar amounts. After intravenous administration, 50 percent of the peptide is removed from the circulation in less than three minutes. Somatostatin secretion occurs in response to a variety of stimuli. Meal ingestion and gastric acid secretion increase somatostatin output from gastric D-cells [<a href="#rid3">3</a>]. Gut somatostatin production is regulated by the autonomic nervous system with catecholamines inhibiting and cholinergic mediators stimulating peptide release [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h1">SOMATOSTATIN PHYSIOLOGY</span><span class="headingEndMark"> — </span>The physiological effects of somatostatin are largely inhibitory (<a class="graphic graphic_table graphicRef67174" href="/d/graphic/67174.html" rel="external">table 1</a>). In the peripheral organs, somatostatin decreases endocrine and exocrine secretion and blood flow, reduces gastrointestinal motility and gallbladder contraction, and inhibits secretion of most gastrointestinal hormones (<a class="graphic graphic_table graphicRef67492" href="/d/graphic/67492.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef76713" href="/d/graphic/76713.html" rel="external">table 4</a>). In pancreatic islets, somatostatin inhibits both alpha and beta cells and finely tunes glucagon and insulin secretion through paracrine regulation [<a href="#rid13">13</a>]. Somatostatin also inhibits neurotransmission in the brain, but depending on the neural pathways affected, somatostatin in the central nervous system may stimulate endocrine secretion. For example, somatostatin inhibits ghrelin release from X/A-like cells of the gastric mucosa, but in the brain, somatostatin receptor activation increases plasma ghrelin levels [<a href="#rid14">14</a>]. In the hypothalamus, somatostatin inhibits growth hormone and thyroid-stimulating hormone release from the anterior pituitary gland. In the brain and peripheral nervous system, somatostatin can function as a neurotransmitter and modulates neurotransmission. It typically co-localizes in GABAergic neurons and potentiates inhibitory neuronal signaling [<a href="#rid15">15</a>]. Somatostatin is also expressed in immune cells including macrophages, lymphocytes, and monocytes and exerts anti-inflammatory and antinociceptive effects [<a href="#rid16">16</a>]. </p><p>Excess somatostatin secretion is rare and occurs with somatostatinomas. The clinical syndrome is manifest by the triad of (i) diabetes mellitus, (ii) diarrhea secondary to malabsorption, and (iii) gallstone disease. These pathophysiologic processes are the direct result of the inhibitory effects of somatostatin on insulin secretion, pancreatic exocrine secretion, and gallbladder contraction, respectively (see  <a class="medical medical_review" href="/d/html/2608.html" rel="external">"Somatostatinoma: Clinical manifestations, diagnosis, and management"</a>). Somatostatin deficiency occurs with persistent <em>Helicobacter pylori</em> infection in the setting of chronic gastritis [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL IMPLICATIONS OF SOMATOSTATIN</span><span class="headingEndMark"> — </span>The clinical utility of somatostatin is hampered by its short half-life in the circulation (less than three minutes). As a result, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> acetate, a synthetic peptide that maintained the biological activity of somatostatin yet remained active for over 90 minutes, was developed as a drug that could be administered parenterally (<a class="graphic graphic_figure graphicRef55724" href="/d/graphic/55724.html" rel="external">figure 1</a>). Octreotide is much more stable in the circulation and is more potent in many of the inhibitory actions than native somatostatin [<a href="#rid18">18</a>]. The clinical use of octreotide has been established for a number of indications (<a class="graphic graphic_table graphicRef76713" href="/d/graphic/76713.html" rel="external">table 4</a>) [<a href="#rid2">2,19</a>].</p><p>Long-acting somatostatin analogues, somatostatin LAR (Sandostatin LAR), lanreotide-PR (Somatuline PR), and <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> (Signifor) have also simplified treatment with somatostatin analogues [<a href="#rid20">20</a>]. These agents are slow-release formulations that require only monthly injection and supply high-dose, stable blood levels of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>. These agents provide for improved patient compliance since they are administered on a weekly to monthly schedule depending upon the indication. An oral form of octreotide has been developed [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H91902057"><span class="h2">Acromegaly</span><span class="headingEndMark"> — </span>Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary tumor. Medical therapy is important for reducing growth hormone secretion and may be used as an adjunct to neurosurgery or radiotherapy [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>). Acromegaly and other pituitary tumors, including Cushing's disease, have been treated with somatostatin analogues [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Secretory diarrhea</span><span class="headingEndMark"> — </span>Secretory diarrhea is a manifestation of a variety of disorders. Human immunodeficiency virus (HIV) infection, for example, can cause serious volume-depleting diarrhea that may respond to <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid24">24</a>]. Given the clinical improvement some patients with profound secretory diarrhea have demonstrated with octreotide treatment, it has been tried in a number of other diseases with variable results (<a class="graphic graphic_table graphicRef76713" href="/d/graphic/76713.html" rel="external">table 4</a>).</p><p>One of the approved indications is for patients with vasoactive intestinal polypeptide secreting tumor (VIPoma), also called pancreatic cholera or watery diarrhea/hypokalemic/achlorhydria (WDHA) [<a href="#rid25">25</a>]. These individuals have high serum VIP levels and respond to therapy with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (see  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Somatostatin analogs'</a>). Octreotide is also effective in carcinoid syndrome in which it reduces serotonin release and improves symptoms of flushing and diarrhea [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Gastrointestinal bleeding</span><span class="headingEndMark"> — </span>Somatostatin has an important role in regulating intestinal blood flow. <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> reduces splanchnic blood flow and, therefore, has been used to treat gastrointestinal bleeding [<a href="#rid28">28,29</a>]. Octreotide may be useful in gastrointestinal angiodysplasia, which is often difficult to manage [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a> and  <a class="medical medical_review" href="/d/html/2557.html" rel="external">"Angiodysplasia of the gastrointestinal tract", section on 'Octreotide'</a>.) </p><p class="headingAnchor" id="H10"><span class="h2">Pancreatic disorders</span><span class="headingEndMark"> — </span>Somatostatin inhibits pancreatic exocrine and endocrine secretion. Although somatostatin/<a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> has been studied, it is not routinely used to prevent post-ERCP pancreatitis [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/d/html/629.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis"</a>.)</p><p>Somatostatin receptor agonists have been investigated in a number of disorders of the pancreas, including acute pancreatitis and pancreatic fistulae. However, the results of many studies of acute pancreatitis indicate no clear benefit on the clinical utility of either somatostatin or <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid34">34</a>] in improving pancreatic fistulae drainage [<a href="#rid35">35</a>], or enterocutaneous fistulae [<a href="#rid36">36,37</a>] (see  <a class="medical medical_review" href="/d/html/5633.html" rel="external">"Management of acute pancreatitis"</a>). A meta-analysis suggested that somatostatin analogues may reduce complications following pancreatic surgery but did not reduce overall mortality [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Diagnostic imaging</span><span class="headingEndMark"> — </span>Most neuroendocrine tumors express somatostatin receptors on their cell surface, providing a rationale for the use of radiolabeled <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> to image these tumors. Conventional imaging techniques, including computed tomography, ultrasound, angiography, and magnetic resonance imaging, are the mainstay of tumor localization. However, because neuroendocrine tumors are frequently small they are often difficult to localize accurately by these methods. Somatostatin receptor scintigraphy appears to be more sensitive for detecting such tumors [<a href="#rid39">39</a>]. <sup>111</sup>In-DTPA-octreotide was initially the most common radiolabeled ligand; however, somatostatin analogues with higher affinity and different specificities for somatostatin receptor subtypes have been labeled with other radioelements such as technetium-99, gallium-68, fluorine-18, and copper-64 and used to image gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) and other solid tumors [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Inhibition of tumor growth</span><span class="headingEndMark"> — </span>Somatostatin and analogues can slow the growth of some gastrointestinal cancers, particularly neuroendocrine tumors. This antitumor activity appears to be related to both direct and indirect effects. Directly, activation of somatostatin receptors in tumor cells induces cell cycle arrest or apoptosis primarily through regulation of MAP kinase and phosphotyrosine phosphatase activities. Somatostatin receptors are also expressed on some tumor blood vessels, providing an indirect mechanism for inhibiting tumor angiogenesis and secretion of growth factors [<a href="#rid42">42,43</a>].</p><p>Non-endocrine solid tumors may express multiple somatostatin receptor subtypes and it has been proposed that other somatostatin analogues with a broader range of binding activity may actually be more effective than <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> or <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> in inhibiting tumor growth [<a href="#rid44">44</a>].</p><p>Radiolabeled somatostatin analogues can be used to deliver isotopes to tumors that contain somatostatin receptors through somatostatin receptors on tumor cells [<a href="#rid45">45-49</a>]. Low-grade neuroendocrine tumors with high somatostatin receptor expression are particularly susceptible to radiolabeled somatostatin analogue therapy with reported response rates of up to approximately 30 percent [<a href="#rid50">50,51</a>]. Loss of somatostatin receptors has been described in pancreatic cancer and may lead to lack of somatostatin inhibitory growth responses [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Other uses</span><span class="headingEndMark"> — </span>As mentioned above, somatostatin exerts some anti-angiogenic effects and induces apoptosis in endothelial cells. These actions have stimulated interest in evaluation of somatostatin analogues in the treatment of proliferative diabetic retinopathy [<a href="#rid53">53</a>].</p><p>Neuropathic pain following nerve injury is accompanied by an increase in spinal G protein-coupled receptors and ion channels that reinforce pain pathways. However, there is often a compensatory increase in inhibitory receptors on nerves that include somatostatin receptors. These inhibitory influences are becoming recognized for their ability to restrain allodynia and hyperalgesia [<a href="#rid54">54</a>]. For these reasons, somatostatin also has antinociceptive effects and in some circumstances may be useful in treating pain [<a href="#rid55">55,56</a>]. Due to their antinociceptive effects and the wide distribution of somatostatin receptors in the brain, somatostatin analogues may be used to treat migraine and cluster headaches [<a href="#rid57">57</a>].</p><p>By virtue of its generalized anti-secretory effects, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> has been used to manage the diarrhea and vasomotor symptoms associated with dumping syndrome following gastric or bariatric surgery [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/89634.html" rel="external">"Postgastrectomy complications", section on 'Dumping syndrome'</a>.)</p><p>The ability of somatostatin to inhibit intracellular adenosine 3’, 5’-cyclic monophosphate (cAMP) renders it effective in reducing cell proliferation and fluid secretion in autosomal dominant polycystic disease [<a href="#rid59">59,60</a>] and polycystic liver disease [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H667400"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Somatostatin is produced by paracrine cells that are scattered throughout the gastrointestinal tract and inhibits gastrointestinal endocrine secretion. In the central and peripheral nervous systems, somatostatin functions as a peptidergic neurotransmitter. (See <a class="local">'Tissue distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The somatostatin receptor is a typical G protein-coupled receptor. Somatostatin receptors can interact with each other and form dimers. Different receptor types can also interact with the somatostatin receptor (receptor heterodimerization), thereby providing a novel pathway for cellular communication. (See <a class="local">'Receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meal ingestion and gastric acid secretion increase somatostatin output from gastric D-cells. In the peripheral nervous systems and peripheral organs, somatostatin decreases endocrine and exocrine secretion and blood flow, reduces gastrointestinal motility and gallbladder contraction, and inhibits secretion of most gastrointestinal hormones (<a class="graphic graphic_table graphicRef67492" href="/d/graphic/67492.html" rel="external">table 3</a>). (See <a class="local">'Somatostatin release'</a> above and <a class="local">'Somatostatin physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Somatostatinomas are characterized by somatostatin excess and the triad of diabetes mellitus, diarrhea secondary to malabsorption, and gallstone disease. Somatostatin deficiency occurs with persistent <em>Helicobacter pylori</em> infection in the setting of chronic gastritis. (See <a class="local">'Somatostatin physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> and other long acting analogues of somatostatin, have a number of established clinical indications including the treatment of secretory diarrhea, gastrointestinal bleeding, inhibition of tumor growth, and imaging neuroendocrine and other solid tumors (<a class="graphic graphic_table graphicRef76713" href="/d/graphic/76713.html" rel="external">table 4</a>). (See <a class="local">'Clinical implications of somatostatin'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77.</a></li><li><a class="nounderline abstract_t">Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.</a></li><li class="breakAll">Chiba T, Yamada T. Gut Somatostatin, 1st ed, Walsh J, Dockray G (Eds), Raven Press, New York 1994.</li><li><a class="nounderline abstract_t">Broglio F, Papotti M, Muccioli G, Ghigo E. Brain-gut communication: cortistatin, somatostatin and ghrelin. Trends Endocrinol Metab 2007; 18:246.</a></li><li><a class="nounderline abstract_t">Kidd M, Drozdov I, Joseph R, et al. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113:690.</a></li><li><a class="nounderline abstract_t">Raulf F, Pérez J, Hoyer D, Bruns C. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 1994; 55 Suppl 3:46.</a></li><li><a class="nounderline abstract_t">Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 2008; 286:35.</a></li><li><a class="nounderline abstract_t">Rocheville M, Lange DC, Kumar U, et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275:7862.</a></li><li><a class="nounderline abstract_t">Yamada T, Soll AH, Park J, Elashoff J. Autonomic regulation of somatostatin release: studies with primary cultures of canine fundic mucosal cells. Am J Physiol 1984; 247:G567.</a></li><li><a class="nounderline abstract_t">Kumar U. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 2011; 40:168.</a></li><li><a class="nounderline abstract_t">Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013; 34:676.</a></li><li><a class="nounderline abstract_t">Hipkin RW, Friedman J, Clark RB, et al. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 1997; 272:13869.</a></li><li><a class="nounderline abstract_t">Huising MO. Paracrine regulation of insulin secretion. Diabetologia 2020; 63:2057.</a></li><li><a class="nounderline abstract_t">Stengel A, Taché Y. Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications. Front Endocrinol (Lausanne) 2012; 3:178.</a></li><li><a class="nounderline abstract_t">Cammalleri M, Bagnoli P, Bigiani A. Molecular and Cellular Mechanisms Underlying Somatostatin-Based Signaling in Two Model Neural Networks, the Retina and the Hippocampus. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">ten Bokum AM, Hofland LJ, van Hagen PM. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw 2000; 11:161.</a></li><li><a class="nounderline abstract_t">Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2005; 21:636.</a></li><li><a class="nounderline abstract_t">Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 1994; 55 Suppl 3:107.</a></li><li><a class="nounderline abstract_t">Mosdell KW, Visconti JA. Emerging indications for octreotide therapy, Part 1. Am J Hosp Pharm 1994; 51:1184.</a></li><li><a class="nounderline abstract_t">van der Hoek J, Hofland LJ, Lamberts SW. Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. Curr Pharm Des 2005; 11:1573.</a></li><li><a class="nounderline abstract_t">Biermasz NR. New medical therapies on the horizon: oral octreotide. Pituitary 2017; 20:149.</a></li><li><a class="nounderline abstract_t">Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers 2019; 5:20.</a></li><li><a class="nounderline abstract_t">Gheorghiu ML, Negreanu F, Fleseriu M. Updates in the Medical Treatment of Pituitary Adenomas. Horm Metab Res 2020; 52:8.</a></li><li><a class="nounderline abstract_t">Cello JP, Grendell JH, Basuk P, et al. Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Ann Intern Med 1991; 115:705.</a></li><li><a class="nounderline abstract_t">Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464.</a></li><li><a class="nounderline abstract_t">Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.</a></li><li><a class="nounderline abstract_t">Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019; 26:R145.</a></li><li><a class="nounderline abstract_t">Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10:958.</a></li><li><a class="nounderline abstract_t">Korula J. Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. ACP J Club 2005; 143:16.</a></li><li><a class="nounderline abstract_t">Becq A, Rahmi G, Perrod G, Cellier C. Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management. Gastrointest Endosc 2017; 86:792.</a></li><li><a class="nounderline abstract_t">Goltstein LCMJ, Grooteman KV, Rocco A, et al. Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2021; 6:922.</a></li><li><a class="nounderline abstract_t">Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1.</a></li><li><a class="nounderline abstract_t">Hu J, Li PL, Zhang T, et al. Role of Somatostatin in Preventing Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis: An Update Meta-analysis. Front Pharmacol 2016; 7:489.</a></li><li><a class="nounderline abstract_t">Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000; 135:112.</a></li><li><a class="nounderline abstract_t">Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232:419.</a></li><li><a class="nounderline abstract_t">Alvarez C, McFadden DW, Reber HA. Complicated enterocutaneous fistulas: failure of octreotide to improve healing. World J Surg 2000; 24:533.</a></li><li><a class="nounderline abstract_t">Stevens P, Foulkes RE, Hartford-Beynon JS, Delicata RJ. Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula. Eur J Gastroenterol Hepatol 2011; 23:912.</a></li><li><a class="nounderline abstract_t">Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92:1059.</a></li><li><a class="nounderline abstract_t">Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.</a></li><li><a class="nounderline abstract_t">Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011; 18 Suppl 1:S27.</a></li><li><a class="nounderline abstract_t">Eychenne R, Bouvry C, Bourgeois M, et al. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020; 25.</a></li><li><a class="nounderline abstract_t">Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008; 13:822.</a></li><li><a class="nounderline abstract_t">Sun L, Coy DH. Somatostatin and its Analogs. Curr Drug Targets 2016; 17:529.</a></li><li><a class="nounderline abstract_t">Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 2011; 7:895.</a></li><li><a class="nounderline abstract_t">Tomassetti P, Migliori M, Caletti GC, et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343:551.</a></li><li><a class="nounderline abstract_t">Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42:442.</a></li><li><a class="nounderline abstract_t">Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16:1197.</a></li><li><a class="nounderline abstract_t">Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000; 44:3.</a></li><li><a class="nounderline abstract_t">Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer 2014; 21:R485.</a></li><li><a class="nounderline abstract_t">Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121:1172.</a></li><li><a class="nounderline abstract_t">Raj N, Reidy-Lagunes D. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas 2014; 43:1185.</a></li><li><a class="nounderline abstract_t">Fogar P, Greco E, Basso D, et al. Killer genes in pancreatic cancer therapy. Cell Mol Biol (Noisy-le-grand) 2005; 51:61.</a></li><li><a class="nounderline abstract_t">Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4:199.</a></li><li><a class="nounderline abstract_t">Taylor BK. Spinal inhibitory neurotransmission in neuropathic pain. Curr Pain Headache Rep 2009; 13:208.</a></li><li><a class="nounderline abstract_t">Pan HL, Wu ZZ, Zhou HY, et al. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther 2008; 117:141.</a></li><li><a class="nounderline abstract_t">Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41:854.</a></li><li><a class="nounderline abstract_t">Lambert GA, Zagami AS. Does somatostatin have a role to play in migraine headache? Neuropeptides 2018; 69:1.</a></li><li><a class="nounderline abstract_t">van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev 2017; 18:68.</a></li><li><a class="nounderline abstract_t">Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2020; 35:1306.</a></li><li><a class="nounderline abstract_t">Sussman CR, Wang X, Chebib FT, Torres VE. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling. Cell Signal 2020; 72:109649.</a></li><li><a class="nounderline abstract_t">Temmerman F, Gevers T, Ho TA, et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013; 38:397.</a></li><li><a class="nounderline abstract_t">Griffiths J, Mills MT, Ong AC. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open 2020; 10:e032620.</a></li></ol></div><div id="topicVersionRevision">Topic 2579 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4682131" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532003" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532003" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632010" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Brain-gut communication: cortistatin, somatostatin and ghrelin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618499" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698537" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006219" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Selective agonism in somatostatin receptor signaling and regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713101" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6149698" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autonomic regulation of somatostatin release: studies with primary cultures of canine fundic mucosal cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870170" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cross-talk and modulation of signaling between somatostatin and growth factor receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183675" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Illuminating somatostatin analog action at neuroendocrine tumor receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153246" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894316" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Paracrine regulation of insulin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335913" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31117258" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Molecular and Cellular Mechanisms Underlying Somatostatin-Based Signaling in Two Model Neural Networks, the Retina and the Hippocampus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903795" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Somatostatin and somatostatin receptors in the immune system: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16220038" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastric secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7698532" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042637" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Emerging indications for octreotide therapy, Part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892663" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28091879" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : New medical therapies on the horizon: oral octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899019" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Updates in the Medical Treatment of Pituitary Adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929038" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628270" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2427948" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30608900" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of carcinoid syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2573572" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15989304" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554655" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508668" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10625786" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28018225" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of Somatostatin in Preventing Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis: An Update Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695655" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effects of somatostatin and octreotide on experimental and human acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973392" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787072" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Complicated enterocutaneous fistulas: failure of octreotide to improve healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814141" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16044410" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644985" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22005114" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887456" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981589" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951062" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Somatostatin and its Analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21732759" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954763" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment of type II gastric carcinoid tumors with somatostatin analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577356" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811995" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932597" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : State of the art and future prospects in the management of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25336571" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274401" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Therapeutic strategies for neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25333401" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171565" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Killer genes in pancreatic cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053337" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The potential role of octreotide in the treatment of diabetic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19457281" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Spinal inhibitory neurotransmission in neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959251" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Modulation of pain transmission by G-protein-coupled receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665953" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Current and novel therapeutic options for irritable bowel syndrome management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29751998" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Does somatostatin have a role to play in migraine headache?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749997" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077332" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32335259" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799922" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31924636" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
